-
公开(公告)号:US06440458B1
公开(公告)日:2002-08-27
申请号:US09403787
申请日:1999-11-05
申请人: Kazunari Yamashita , Eiji Hashimoto , Yukihiro Nomura , Fumio Shimojo , Shigeki Tamura , Takeo Hirose , Satoshi Ueda , Takashi Saitoh , Rinta Ibuki , Toshio Ideno
发明人: Kazunari Yamashita , Eiji Hashimoto , Yukihiro Nomura , Fumio Shimojo , Shigeki Tamura , Takeo Hirose , Satoshi Ueda , Takashi Saitoh , Rinta Ibuki , Toshio Ideno
IPC分类号: A61K922
CPC分类号: A61K31/453 , A61K9/141 , A61K9/143 , A61K9/145 , A61K9/146 , A61K9/1617 , A61K9/1623 , A61K9/1635 , A61K9/1641 , A61K9/1647 , A61K9/1652 , A61K9/4858 , A61K31/407 , A61K31/436
摘要: Providing an oral formulation of a macrolide compound where the dissolution of the macrolide compound is under sustained release; and a sustained-release formulation containing a composition in solid solution, where the macrolide compound is present at an amorphous state in a solid base.
-
公开(公告)号:US20050169993A1
公开(公告)日:2005-08-04
申请号:US11059439
申请日:2005-02-17
申请人: Kazunari Yamashita , Eiji Hashimoto , Yukihiro Nomura , Fumio Shimojo , Shigeki Tamura , Takeo Hirose , Satoshi Ueda , Takashi Saitoh , Rinta Ibuki , Toshio Ideno
发明人: Kazunari Yamashita , Eiji Hashimoto , Yukihiro Nomura , Fumio Shimojo , Shigeki Tamura , Takeo Hirose , Satoshi Ueda , Takashi Saitoh , Rinta Ibuki , Toshio Ideno
IPC分类号: C07H15/04 , A61K20060101 , A61K9/10 , A61K9/14 , A61K9/16 , A61K9/20 , A61K9/22 , A61K9/48 , A61K9/52 , A61K31/40 , A61K31/405 , A61K31/407 , A61K31/4353 , A61K31/436 , A61K31/453 , A61K31/706 , A61K47/04 , A61K47/12 , A61K47/14 , A61K47/26 , A61K47/32 , A61K47/36 , A61K47/38 , A61K47/40 , A61P31/00 , A61P37/06 , C07D498/18 , G01N33/15 , A61K31/4745
CPC分类号: A61K31/453 , A61K9/141 , A61K9/143 , A61K9/145 , A61K9/146 , A61K9/1617 , A61K9/1623 , A61K9/1635 , A61K9/1641 , A61K9/1647 , A61K9/1652 , A61K9/4858 , A61K31/407 , A61K31/436
摘要: A sustained-release formulation is provided comprising a solid dispersion composition comprising a tricyclic compound or a pharmaceutically acceptable salt thereof in a mixture comprising a water-soluble polymer and a water-insoluble polymer, and an excipient.
摘要翻译: 提供了包含在包含水溶性聚合物和水不溶性聚合物和赋形剂的混合物中的包含三环化合物或其药学上可接受的盐的固体分散体组合物的缓释制剂。
-
公开(公告)号:US06576259B2
公开(公告)日:2003-06-10
申请号:US09978025
申请日:2001-10-17
申请人: Kazunari Yamashita , Eiji Hashimoto , Yukihiro Nomura , Fumio Shimojo , Shigeki Tamura , Takeo Hirose , Satoshi Ueda , Takashi Saitoh , Rinta Ibuki , Toshio Ideno
发明人: Kazunari Yamashita , Eiji Hashimoto , Yukihiro Nomura , Fumio Shimojo , Shigeki Tamura , Takeo Hirose , Satoshi Ueda , Takashi Saitoh , Rinta Ibuki , Toshio Ideno
IPC分类号: A61K900
CPC分类号: A61K31/453 , A61K9/141 , A61K9/143 , A61K9/145 , A61K9/146 , A61K9/1617 , A61K9/1623 , A61K9/1635 , A61K9/1641 , A61K9/1647 , A61K9/1652 , A61K9/4858 , A61K31/407 , A61K31/436
摘要: Sustained release formulation containing tacrolimus or its hydrate is provided. The time (T63.2%) required for 63.2% of the maximum amount of tacrolimus or its hydrate to be dissolved is 0.7 to 15 hours. The time is measured in accordance to the Japanese Pharmacopoeia, the 13-th edition, Dissolution Test, No. 2 (Puddle method, 50 rpm) using an aqueous 0.005% hydroxypropyl cellulose solution. This aqueous test solution is adjusted to pH 4.5, accordingly. The formulation further comprise a solid base which is a water-soluble polymer and/or wax. The formulation is in the form of a powder, fine powder, granule, tablet or capsule. Furthermore, the formulation is administered to a patient once a day for preventing organ or tissue rejection by transplantation or autoimmune diseases.
摘要翻译: 提供含他克莫司或其水合物的缓释制剂。 最高量的他克莫司或其水合物溶解63.2%所需的时间(T63.2%)为0.7〜15小时。 时间根据日本药典,第13版,溶出度试验,第2号(Puddle法,50rpm),使用0.005%羟丙基纤维素水溶液测量。 相应地将该水性测试溶液调节至pH 4.5。 制剂还包含固体碱,其为水溶性聚合物和/或蜡。 制剂为粉末,细粉,颗粒,片剂或胶囊的形式。 此外,该制剂每天一次施用于患者,以通过移植或自身免疫疾病预防器官或组织排斥反应。
-
公开(公告)号:US06316473B1
公开(公告)日:2001-11-13
申请号:US09402469
申请日:1999-10-12
申请人: Fumio Shimojo , Sumihisa Kimura , Takeo Hirose , Satoshi Ueda , Rinta Ibuki , Norio Ohnishi
发明人: Fumio Shimojo , Sumihisa Kimura , Takeo Hirose , Satoshi Ueda , Rinta Ibuki , Norio Ohnishi
IPC分类号: A61K3140
CPC分类号: A61K31/436 , A61K9/4866 , A61K47/14 , A61K47/44
摘要: Provided is a medicinal composition having a very satisfactory drug release profile and a very satisfactory drug absorption profile after oral administration characterized by its comprising an insoluble drug and two or more surfactants, at least one of the surfactants having as dissolved therein the insoluble drug and the other surfactant or surfactants.
摘要翻译: 本发明提供一种具有非常令人满意的药物释放特性和口服给药后非常令人满意的药物吸收曲线的药物组合物,其特征在于其包含不溶性药物和两种或更多种表面活性剂,至少一种表面活性剂溶解有不溶性药物和 其他表面活性剂或表面活性剂。
-
公开(公告)号:US4650210A
公开(公告)日:1987-03-17
申请号:US786942
申请日:1985-10-11
申请人: Takeo Hirose , Takuji Nozue
发明人: Takeo Hirose , Takuji Nozue
CPC分类号: B62K5/01 , B62D61/08 , B62K2005/001
摘要: A saddle-type vehicle for operation on irregular and uneven ground, wherein a pair of rear suspension arm assemblies each connected pivotally to the rear part of a main frame of the vehicle. The assemblies have suspension arm portions connected operatively at their middle points to the lower end of a shock absorber, and rear end portions disposed at a higher and/or inner position than front end portion thereof. The main frame has a pair of lower tubes connected rigidly with a corresponding pair of upper tubes by way of connecting members. The pair of lower tubes are formed at their midway portions to provide holding members for the front end portions of the suspension and these holding members are directed in the same direction as swing axes for the suspension assemblies.
摘要翻译: 一种用于在不规则和不均匀地面上操作的鞍形车辆,其中一对后悬架臂组件各自枢转地连接到车辆的主框架的后部。 组件具有在其中点处可操作地连接到减震器的下端的悬挂臂部分,以及设置在比其前端部分更高和/或内部位置的后端部分。 主框架具有通过连接构件与相应的一对上管刚性连接的一对下管。 一对下管形成在其中间部分处,以提供用于悬架的前端部分的保持构件,并且这些保持构件沿与用于悬架组件的摆动轴线相同的方向指向。
-
公开(公告)号:US4699229A
公开(公告)日:1987-10-13
申请号:US794669
申请日:1985-11-04
CPC分类号: B62K5/01 , B62K13/00 , B62M27/02 , B62M2027/021
摘要: An off-road vehicle is equipped with an endless articulated steel band drive system including a drive wheel, a plurality of idle wheels and an endless belt extending around the drive wheel and the idle wheel. A back slider plate extends along the inner surface of the endless belt to urge the ground contact surface of the endless belt against the ground. The leading portion of the back plate rises upwardly at an angle of with respect to the ground. One of the idle wheels is rotatably mounted to the rear end of the back plate and the back plate is mounted to the vehicle frame by a leaf spring.
摘要翻译: 越野车辆配备有环形铰接钢带驱动系统,其包括驱动轮,多个惰轮和围绕驱动轮和空转轮延伸的环形带。 后滑块板沿着环形带的内表面延伸,以将环形带的接地表面推向地面。 背板的前导部分以相对于地面的角度向上升起。 空闲轮中的一个可旋转地安装到后板的后端,并且后板通过板簧安装到车架上。
-
公开(公告)号:US06346537B1
公开(公告)日:2002-02-12
申请号:US09308672
申请日:1999-06-04
申请人: Takehisa Hata , Yuji Tokunaga , Fumio Shimojo , Sumihisa Kimura , Takeo Hirose , Satoshi Ueda
发明人: Takehisa Hata , Yuji Tokunaga , Fumio Shimojo , Sumihisa Kimura , Takeo Hirose , Satoshi Ueda
IPC分类号: A61K3144
摘要: To provide a pharmaceutical composition comprising a water-insoluble active substance, surfactant(s) and solid carrier(s), which is improved in dissolution and oral absorption characteristics.
摘要翻译: 提供包含水溶性活性物质,表面活性剂和固体载体的药物组合物,其溶出度和口服吸收特性得到改善。
-
公开(公告)号:US08551522B2
公开(公告)日:2013-10-08
申请号:US12265108
申请日:2008-11-05
申请人: Kazunari Yamashita , Eiji Hashimoto , Yukihiro Nomura , Fumio Shimojo , Shigeki Tamura , Takeo Hirose , Satoshi Ueda , Takashi Saitoh , Rinta Ibuki , Toshio Ideno
发明人: Kazunari Yamashita , Eiji Hashimoto , Yukihiro Nomura , Fumio Shimojo , Shigeki Tamura , Takeo Hirose , Satoshi Ueda , Takashi Saitoh , Rinta Ibuki , Toshio Ideno
CPC分类号: A61K31/453 , A61K9/141 , A61K9/143 , A61K9/145 , A61K9/146 , A61K9/1617 , A61K9/1623 , A61K9/1635 , A61K9/1641 , A61K9/1647 , A61K9/1652 , A61K9/4858 , A61K31/407 , A61K31/436
摘要: A sustained-release formulation is provided comprising a solid dispersion composition comprising a tricyclic compound or a pharmaceutically acceptable salt thereof in a mixture comprising a water-soluble polymer and a water-insoluble polymer, and an excipient.
摘要翻译: 提供了包含在包含水溶性聚合物和水不溶性聚合物和赋形剂的混合物中的包含三环化合物或其药学上可接受的盐的固体分散体组合物的缓释制剂。
-
公开(公告)号:US20090074858A1
公开(公告)日:2009-03-19
申请号:US12265108
申请日:2008-11-05
申请人: Kazunari YAMASHITA , Eiji HASHIMOTO , Yukihiro NOMURA , Fumio SHIMOJO , Shigeki TAMURA , Takeo HIROSE , Satoshi UEDA , Takashi SAITOH , Rinta IBUKI , Toshio IDENO
发明人: Kazunari YAMASHITA , Eiji HASHIMOTO , Yukihiro NOMURA , Fumio SHIMOJO , Shigeki TAMURA , Takeo HIROSE , Satoshi UEDA , Takashi SAITOH , Rinta IBUKI , Toshio IDENO
IPC分类号: A61K9/48 , A61K9/14 , A61K9/20 , A61K31/436
CPC分类号: A61K31/453 , A61K9/141 , A61K9/143 , A61K9/145 , A61K9/146 , A61K9/1617 , A61K9/1623 , A61K9/1635 , A61K9/1641 , A61K9/1647 , A61K9/1652 , A61K9/4858 , A61K31/407 , A61K31/436
摘要: A sustained-release formulation is provided comprising a solid dispersion composition comprising a tricyclic compound or a pharmaceutically acceptable salt thereof in a mixture comprising a water-soluble polymer and a water-insoluble polymer and an excipient.
摘要翻译: 提供了包含固体分散体组合物的缓释制剂,其包含三环化合物或其药学上可接受的盐在包含水溶性聚合物和水不溶性聚合物和赋形剂的混合物中。
-
公开(公告)号:US06884433B2
公开(公告)日:2005-04-26
申请号:US10412281
申请日:2003-04-14
申请人: Kazunari Yamashita , Eiji Hashimoto , Yukihiro Nomura , Fumio Shimojo , Shigeki Tamura , Takeo Hirose , Satoshi Ueda , Takashi Saitoh , Rinta Ibuki , Toshio Ideno
发明人: Kazunari Yamashita , Eiji Hashimoto , Yukihiro Nomura , Fumio Shimojo , Shigeki Tamura , Takeo Hirose , Satoshi Ueda , Takashi Saitoh , Rinta Ibuki , Toshio Ideno
IPC分类号: C07H15/04 , A61K20060101 , A61K9/10 , A61K9/14 , A61K9/16 , A61K9/20 , A61K9/22 , A61K9/48 , A61K9/52 , A61K31/40 , A61K31/405 , A61K31/407 , A61K31/4353 , A61K31/436 , A61K31/453 , A61K31/706 , A61K47/04 , A61K47/12 , A61K47/14 , A61K47/26 , A61K47/32 , A61K47/36 , A61K47/38 , A61K47/40 , A61P31/00 , A61P37/06 , C07D498/18 , G01N33/15 , A61K9/00 , A61K31/44
CPC分类号: A61K31/453 , A61K9/141 , A61K9/143 , A61K9/145 , A61K9/146 , A61K9/1617 , A61K9/1623 , A61K9/1635 , A61K9/1641 , A61K9/1647 , A61K9/1652 , A61K9/4858 , A61K31/407 , A61K31/436
摘要: Sustained release formulation containing tacrolimus or its hydrate is provided. The time (T63.2%) required for 63.2% of the maximum amount of tacrolimus or its hydrate to be dissolved is 0.7 to 15 hours. The time is measured in accordance to the Japanes Pharmacopocia, the 13-th edition, Dissolution Test, No. 2 (Puddles method, 50 rpm) using an aqueous 0.005% hydroxypropyl cellulose solution. This aqueous test solution is adjusted to pH 4.5, accordingly. The formulation further comprises a solid base which is a water-soluble or water-insoluble polymer. The formulation is in the form of a powder, fine powder, granule, tablet or capsule. The formulation is administered to a patient once a day for preventing organ or tissue rejection by transplantation or autoimmune disease. In addition, a solid dispersion composition is provided. The solid dispersion comprises tacrolimus or its hydrate in a mixture containing water-soluble or water-insoluble polymer and an excipient.
摘要翻译: 提供含他克莫司或其水合物的缓释制剂。 最高量的他克莫司或其水合物溶解63.2%所需的时间(T63.2%)为0.7〜15小时。 该时间根据Japanes Pharmacopocia,第13版,溶出度试验,2号(Puddles法,50rpm),使用0.005%羟丙基纤维素水溶液测量。 相应地将该水性测试溶液调节至pH 4.5。 该制剂还包含固体碱,其为水溶性或水不溶性聚合物。 制剂为粉末,细粉,颗粒,片剂或胶囊的形式。 该制剂每天一次施用于患者,以通过移植或自身免疫疾病预防器官或组织排斥反应。 此外,提供了固体分散体组合物。 固体分散体包含他克莫司或其水合物,其含有水溶性或水不溶性聚合物和赋形剂的混合物。
-
-
-
-
-
-
-
-
-